RxDoctor Payments Data

Alla Brodech, MD

Internal Medicine · Skokie, ILNPI 1225076953

Payments from drug & device makers

$1,265in general payments, 2019–2025

Across 27 payments — averaging $46.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$918
  • Novartis$207
  • Pfizer$54
  • Novo Nordisk$35
  • Johnson & Johnson$35
  • AbbVie$16

What the payments were for

  • Food & beverage$1,265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)15$918
Novartis6$207
Pfizer2$54
Novo Nordisk2$35
Johnson & Johnson1$35
AbbVie1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,265 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$141,612
Medicare patients
115
Services billed
2,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$56,165
ProliaDenosumab30$50,932
OzempicSemaglutide27$26,786
Repatha SureclickEvolocumab36$19,939
JardianceEmpagliflozin14$15,943
TrulicityDulaglutide11$10,899
LinzessLinaclotide17$10,509
CreonLipase/Protease/Amylase11$8,801
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$7,852
Repatha SyringeEvolocumab12$6,942
BrilintaTicagrelor13$5,450
Breo ElliptaFluticasone/Vilanterol12$4,753
Advair DiskusFluticasone Propion/Salmeterol17$3,361
SynthroidLevothyroxine Sodium46$2,772
Esomeprazole Magnesium23$2,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$56,16581 claims
AmgenProlia$918$50,93230 claims
Novo NordiskOzempic$35$26,78627 claims
AbbVieLinzess, Creon, Synthroid$16$22,08174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →